<DOC>
	<DOCNO>NCT02616055</DOCNO>
	<brief_summary>Subjects receive tesevatinib Study KD019-101 complete 24 month treatment continue dose tesevatinib receive 24 month KD019-101 study .</brief_summary>
	<brief_title>Long-Term Treatment Follow Subjects Completing 24 Months Treatment With Tesevatinib Study KD019-101</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<criteria>The subject must receive 24 month treatment tesevatinib study KD019101 . ( Twentyfour month study drug treatment include day without treatment allow KD019101 protocol . ) Sexually active subject ( male female ) agree use two form accept method contraception course study 3 month last dose study drug . Effective birth control include ( ) IUD plus one barrier method ; ( b ) stable dos hormonal contraception least 3 month ( eg , oral , injectable , implant , transdermal ) plus one barrier method ; ( c ) 2 barrier method . Effective barrier method male female condom , diaphragm , spermicide ( creams gel contain chemical kill sperm ) . Female subject childbearing potential negative pregnancy test screening . Females childbearing potential define sexually mature woman without prior hysterectomy evidence menses past 12 month . However , woman amenorrheic 12 month still consider childbearing potential amenorrhea possibly due prior chemotherapy , antiestrogens , ovarian suppression .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>